Results 271 to 280 of about 185,231 (352)

Reperfusion therapy for acute coronary occlusion.

Journal of Nippon Medical School, 1991
openaire   +3 more sources

Elevated Hemoglobin Levels and Risk of ST‐Segment Elevation Myocardial Infarction in High‐Altitude Acute Coronary Syndrome: A Retrospective Analysis

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background High‐altitude populations typically exhibit elevated hemoglobin (Hb) levels due to chronic hypoxic exposure; however, the impact of this elevation on the risk of ST‐segment elevation myocardial infarction (STEMI) remains unclear. Existing evidence is primarily derived from low‐altitude populations and cannot be directly extrapolated
Jing Li, Lin‐Feng Liu, Gusang Lamu, Yang Jin, Gesang Gawa, Zhen‐Long Chang, Xiao‐Xia Liu, Zhen‐Zhong Yang, Gesang Luobu, Baima Lamu, Dawa Ciren   +10 more
wiley   +1 more source

Catalytic neural stem cell exosomes for multi-stage targeting and synergistical therapy of retinal ischemia-reperfusion injury

Weiqiang Yang, Xiaojun Wang, Di-Wei Zheng, Jing Feng, Wenjun Kong, Yue Li, Guanghui Ma, Wei Wei, Yong Tao   +8 more
openalex   +1 more source

Coronary Slow Flow and No‐Reflow During Percutaneous Coronary Intervention: Contemporary Insights Into Imaging‐Guided Prediction, Prevention, and Management

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Coronary slow flow (SF) and no‐reflow (NR) are clinically significant complications of percutaneous coronary intervention (PCI), particularly in ST‐segment elevation myocardial infarction (STEMI) and saphenous vein graft (SVG) interventions. Angiographically defined as impaired myocardial perfusion despite restored epicardial patency, SF/NR ...
Bharat Khialani, Eran Sim, George Touma, Sarah Fairley, Cuneyt Ada, Bernard Wong   +5 more
wiley   +1 more source

Reperfusion therapy in ischemic stroke

Consilium Medicum, 2015
N.A. Shamalov, M.A. Kholopov
openaire   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Blood-brain barrier disruption and hemorrhagic transformation in acute stroke before endovascular reperfusion therapy. [PDF]

Front Neurol
Liang Y, Yu Y, Liu J, Li X, Chen X, Zhou H, Guo ZN.   +6 more
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Evaluation of demographic/clinical features and hemorrhagic complications in patients with ischemic stroke who underwent reperfusion therapy. [PDF]

Nagoya J Med Sci
Kömürcü HF, Gözke E, Aslan IK, Ak PD, Salt I.   +4 more
europepmc   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source